# Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

> **NCT03534180** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma
- Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Romidepsin
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03534180
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-21
- **Primary completion:** 2021-04-21
- **Final completion:** 2023-07-26
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03534180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03534180, "Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03534180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*